Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis?

Hepatology. 2017 Feb;65(2):741-744. doi: 10.1002/hep.28946. Epub 2016 Dec 29.

Authors

Melanie Tran¹, Li Wang^{1

2

3

4}

Affiliations

¹ Department of Physiology and Neurobiology and the Institute for Systems Genomics, University of Connecticut, Storrs, CT.
² Veterans Affairs Connecticut Healthcare System, West Haven, CT.
³ Department of Internal Medicine, Section of Digestive Diseases, Yale University, New Haven, CT.
⁴ School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Atherosclerosis*
Fatty Liver*
Humans

Grants and funding